2 results
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…
Approved WMORecruiting
to investigate (1) the additional effect of tDCS on language and communication, when administered during aphasia therapy in the sub-acute phase post stroke (2) its cost-effectiveness, (3) its effect on neural reorganisation of language, and (4) the…